vivocapital.netHome - Vivo Capital | Healthcare Focused Investment Firm

Skip to content English | 简体中文 | LP ACCESS Search for: About Team Portfolio News Contact Search for: About Team Portfolio News Contact Loading... Vivo is a global healthcare investment firm that has raised over $4 billion in capital since inception and has been investing for over 20 years. Home artrix 2021-01-10T22:06:00-08:00 Vivo Capital is a global healthcare investment firm that has been investing for over 20 years. Our investments across multiple funds and strategies are driven by a value and growth-oriented investment strategy, combined with extensive medical and scientific expertise. Vivo is currently making investments from its $1.4B Vivo Capital Fund IX into private healthcare companies, from its $635M Vivo Opportunity Fund into public healthcare companies, and from its $100M Vivo Innovation (PANDA) Fund into early-stage innovative healthcare companies. Vivo’s Three Fund Vehicles Private Equity VIEW MORE Vivo Capital Fund IX and its predecessor funds are growth capital and private equity-focused investment vehicles investing in the healthcare industry. Vivo invests in product-driven companies that develop and commercialize therapeutics, including pharmaceuticals, biotechnology and medical devices. Our growth capital investments help our portfolio companies accelerate revenue ramp or fund product development to drive value creation. Our private equity investments focus primarily on buyouts, privatizations, and spin-off opportunities. We invest in structures ranging from minority equity investments to control transactions with a primary focus on the U.S. and Greater China. Public Equity VIEW MORE Vivo Opportunity Fund primarily invests in the global public equities of small and mid-cap biotechnology, pharmaceutical, healthcare and life science companies. The fund is long only and often invests directly into companies through various financing structures, including follow-ons, secondaries, PIPEs, ATM purchases, and IPOs. Venture Capital VIEW MORE Vivo Innovation Fund (i.e., Vivo PANDA Fund) focuses on investing in venture stage companies with the potential to develop game changing healthcare technologies or products. The fund typically invests in early stage (i.e. Series A) financing rounds. Our Team artrix 2020-07-08T20:46:41-07:00 Frank Kung Gallery Frank Kung Partners , US Team Ph.D., M.B.A. Partner Frank Kung artrix 2021-03-02T23:21:04-08:00 Edgar G. Engleman Gallery Edgar G. Engleman Partners , US Team M.D. Partner Chief Scientific Advisor Edgar G. Engleman artrix 2021-01-10T22:40:23-08:00 Shan Fu Gallery Shan Fu Partners , US Team M.A. Partner Shan Fu artrix 2021-01-11T09:44:24-08:00 Hongbo Lu Gallery Hongbo Lu Partners , US Team Ph.D. Partner Hongbo Lu artrix 2021-03-02T23:22:34-08:00 Jack B. Nielsen Gallery Jack B. Nielsen Partners , US Team M.Sc. Partner Jack B. Nielsen artrix 2021-03-02T23:22:40-08:00 Michael Chang Gallery Michael Chang Partners , US Team M.B.A. Partner Michael Chang artrix 2021-03-02T23:22:01-08:00 Mahendra G. Shah Gallery Mahendra G. Shah Investment team , US Team Ph.D. Senior Fellow Mahendra G. Shah artrix 2021-03-02T23:22:22-08:00 Gaurav Aggarwal Gallery Gaurav Aggarwal Investment team , US Team M.D. Managing Director Gaurav Aggarwal artrix 2021-03-02T23:23:28-08:00 DanDan Dong Gallery DanDan Dong Investment team , US Team Ph.D. Managing Director DanDan Dong artrix 2021-03-02T23:23:18-08:00 Joseph Siletto Gallery Joseph Siletto Investment team , US Team M.B.A. Managing Director Joseph Siletto artrix 2021-03-02T23:23:43-08:00 Daisy Xu Gallery Daisy Xu Investment team , US Team M.S. General Director Daisy Xu artrix 2021-03-02T23:23:56-08:00 David Liu Gallery David Liu Investment team , US Team Ph.D. Managing Director David Liu More Team Our Portfolio News Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work Gallery Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work All News , Portfolio News Bolt Biotherapeutics strikes a major upsized $230M IPO for next-gen cancer work Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health Gallery Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health All News , Portfolio News Vivo Capital and an Investor Syndicate Completes Sale of Surgical Specialties Corporation to GTCR-backed Corza Health Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B Gallery Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B All News , Vivo News Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! Gallery Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! All News , Portfolio News Congratulations to Prof. Frances Arnold, the first American woman to win the Nobel Prize in Chemistry and co-founder of Vivo portfolio company Provivi, for her recent appoint as Co-Chair of President-elect Biden’s Council of Advisors on Science and Technology (PCAST)! More News VISITING VIVO A NOTE ABOUT CURRENT CORONAVIRUS DISEASE (COVID-19) OUTBREAK An outbreak of respiratory illness (COVID-19) caused by a novel, previously unknown coronavirus is currently affecting the global community. To ensure the safety of all of our colleagues, clients, and visitors, the firm has adopted the following visitor policy: Vivo respectfully requests that clients and prospective visitors should refrain from visiting our offices if: They have been in a country within the past 30 days that has been substantially impacted by the coronavirus, including (currently): China, Japan, South Korea, Italy, Iran They have any reason to believe that they may have been exposed to the coronavirus within the past 30 days Our team would be happy to arrange alternative communication methods, for example via teleconference or video conference. Vivo staff members are requested to work under these same guidelines. Much is still unknown about this outbreak, and health officials are urging vigilance and caution. Additional information about the coronavirus is available on the websites of the World Health Organization and the U.S. Centers for Disease Control and Prevention. Palo Alto Global Headquarters 192 Lytton Avenue Palo Alto, CA 94301 Phone: (650) 688-0818 Beijing Suite 1801, West Tower Twin Towers B12 Jianguomenwai Ave Chaoyang District Beijing, 100022 Phone: (86) 10-5764 2288 Shanghai Suite 2504, Hong Yi Plaza No. 288, Jiu Jiang Road Huang Pu District Shanghai, 200001 Phone: (86) 21-6888-0039 Taipei Rm B3, 5F, No.335, Sec. 2 Dunhua S. Rd. Da’an District Taipei, 10669 Phone: (886) 2 2378 2268 Hong Kong Room 1001, Nan Fung Tower 88 Connaught Road Central Central, Hong Kong Phone: (852)3529 1820 Email: info@vivocapital.com Vivo Capital®, SEC registered, effective 6/19/2014. All rights reserved. Go to Top...